NCT03519230 2026-03-16Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian CancerBeOne MedicinesPhase 3 Active not recruiting224 enrolled
NCT05652283 2024-11-27Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian CancerAnhui Provincial Cancer HospitalPhase 2 Active not recruiting37 enrolled